X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (36) 36
hematology (28) 28
male (24) 24
female (22) 22
middle aged (22) 22
index medicus (21) 21
adult (17) 17
oncology (17) 17
aged (13) 13
cancer (9) 9
hematology, oncology and palliative medicine (9) 9
transplantation (8) 8
treatment outcome (8) 8
abridged index medicus (7) 7
acute myeloid-leukemia (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
chemotherapy (7) 7
leukemia, myeloid, acute - drug therapy (7) 7
retrospective studies (7) 7
therapy (7) 7
antineoplastic agents - therapeutic use (6) 6
chronic myeloid-leukemia (5) 5
dasatinib (5) 5
fatal outcome (5) 5
leukemia (5) 5
tyrosine kinase inhibitor (5) 5
acute promyelocytic leukemia (4) 4
aged, 80 and over (4) 4
animals (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
article (4) 4
carcinoma (4) 4
cyclophosphamide (4) 4
disease-free survival (4) 4
further section (4) 4
histone deacetylase inhibitors (4) 4
imatinib (4) 4
leukemia, myeloid, acute - genetics (4) 4
medicine, research & experimental (4) 4
mutation (4) 4
non-hodgkins-lymphoma (4) 4
remission induction (4) 4
survival rate (4) 4
transplantation, autologous (4) 4
acute myeloid leukemia (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
apoptosis (3) 3
care and treatment (3) 3
chronic myeloid leukemia (3) 3
cyclophosphamide - administration & dosage (3) 3
diagnosis (3) 3
expression (3) 3
graft vs host disease - etiology (3) 3
hydroxamic acids - administration & dosage (3) 3
immunology (3) 3
indoles (3) 3
lymphoma (3) 3
mice (3) 3
mortality (3) 3
nilotinib (3) 3
progenitor cells (3) 3
protein kinase inhibitors - therapeutic use (3) 3
recurrence (3) 3
risk factors (3) 3
stem cells (3) 3
survival (3) 3
vorinostat (3) 3
activating mutation (2) 2
acute myelogenous leukemia (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antibodies, monoclonal, humanized - pharmacokinetics (2) 2
antibodies, monoclonal, murine-derived (2) 2
antifungal agents - therapeutic use (2) 2
antimetabolites, antineoplastic - therapeutic use (2) 2
antineoplastic agents - pharmacology (2) 2
apoptosis - drug effects (2) 2
asp816val mutation (2) 2
aurora kinase (2) 2
bcr-abl (2) 2
benzodiazepines - administration & dosage (2) 2
benzodiazepines - adverse effects (2) 2
benzodiazepines - pharmacokinetics (2) 2
blotting, western (2) 2
bms-354825 (2) 2
breast-cancer (2) 2
brief report (2) 2
case report (2) 2
cell line, tumor (2) 2
children (2) 2
chronic lymphocytic-leukemia (2) 2
clinical trials (2) 2
clinical trials and observations (2) 2
cml (2) 2
collection (2) 2
colony-stimulating factor (2) 2
combination (2) 2
combined modality therapy (2) 2
cytogenetics (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3595 - 3595
Abstract Background: There have been significant advances in the management of acute myeloid leukemia (AML) in the past decade. However, management of AML in... 
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 07/2018, Volume 53, Issue 7, pp. 826 - 831
Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total... 
CRITERIA | ONCOLOGY | WORKING GROUP-REPORT | CLINICAL-TRIALS | GVHD | IMMUNOLOGY | HEMATOLOGY | CONSENSUS DEVELOPMENT PROJECT | TRANSPLANTATION | Systemic scleroderma | Scleroderma (Disease) | Research | Graft-versus-host reaction | Salvage | Intestine | Vagina | Scleroderma | Kinases | Steroid hormones | Steroids
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5294 - 5294
Background: Classical Hodgkin lymphoma (CHL) and aggressive non-Hodgkin lymphomas (NHL) are generally considered curable hematologic malignancies but curative... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5894 - 5894
Background: The incorporation of crossover in randomized controlled trials is accepted as an ethical obligation, especially in cancer clinical trials. The more... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e14582 - e14582
Journal Article
Cancer, ISSN 0008-543X, 07/2017, Volume 123, Issue 13, pp. 2482 - 2488
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2017, Volume 7, Issue 1, pp. 12892 - 7
Indoleamine 2,3 dioxygenase-1 (IDO-1) is an enzyme in the kynurenine pathway which augments tumor-induced immune tolerance. Previous studies in childhood acute... 
DENDRITIC CELLS | MICROENVIRONMENT | PATHWAY | TOLERANCE | BLASTS | MULTIDISCIPLINARY SCIENCES | LEVEL | 2,3-DIOXYGENASE | CARCINOMA | CANCER | Immunohistochemistry | Dioxygenase | Cell survival | Myeloid leukemia | Leukemia | Mortality | Clinical trials | Gene expression | Immunological tolerance | Bone marrow | Cytogenetics | Children | Acute myeloid leukemia
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 114, Issue 13, pp. 2733 - 2743
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. e18018 - e18018
Journal Article
Blood, ISSN 0006-4971, 01/2018, Volume 131, Issue 4, pp. 387 - 396
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 4924 - 4924
Abstract Introduction: Newly diagnosed acute promyelocytic leukemia (APL) represents a medical emergency that's associated with a high rate of early mortality... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 4045 - 4045
Imatinib (IM) can be safely discontinued in patients with chronic myeloid leukemia (CML) with sustained complete molecular remission. Previous publications... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1592 - 1592
Abstract The second-generation TKIs (2G-TKIs) Dasatinib (DAS) and Nilotinib (NIL) yield faster responses in newly diagnosed chronic phase (CP) CML as compared... 
Journal Article
Blood, ISSN 0006-4971, 09/2018, Volume 132, Issue 11, pp. 1125 - 1133
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.